IN8bio Statistics
Total Valuation
IN8bio has a market cap or net worth of $45.45 million. The enterprise value is $38.15 million.
Market Cap | 45.45M |
Enterprise Value | 38.15M |
Important Dates
The last earnings date was Thursday, May 9, 2024, after market close.
Earnings Date | May 9, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
IN8bio has 44.12 million shares outstanding. The number of shares has increased by 75.02% in one year.
Shares Outstanding | 44.12M |
Shares Change (YoY) | +75.02% |
Shares Change (QoQ) | +24.98% |
Owned by Insiders (%) | 22.86% |
Owned by Institutions (%) | 38.27% |
Float | 25.25M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 2.59 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.10, with a Debt / Equity ratio of 0.33.
Current Ratio | 4.10 |
Quick Ratio | n/a |
Debt / Equity | 0.33 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -151.40% and return on invested capital (ROIC) is -133.93%.
Return on Equity (ROE) | -151.40% |
Return on Assets (ROA) | -107.80% |
Return on Capital (ROIC) | -133.93% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.00M |
Employee Count | 31 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.95% in the last 52 weeks. The beta is 0.05, so IN8bio's price volatility has been lower than the market average.
Beta (1Y) | 0.05 |
52-Week Price Change | -62.95% |
50-Day Moving Average | 1.10 |
200-Day Moving Average | 1.13 |
Relative Strength Index (RSI) | 47.79 |
Average Volume (30 Days) | 347,266 |
Short Selling Information
The latest short interest is 179,930, so 0.41% of the outstanding shares have been sold short.
Short Interest | 179,930 |
Short Previous Month | 512,019 |
Short % of Shares Out | 0.41% |
Short % of Float | 0.71% |
Short Ratio (days to cover) | 0.27 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -31.13M |
Pretax Income | -31.04M |
Net Income | -31.04M |
EBITDA | -28.50M |
EBIT | -31.04M |
Earnings Per Share (EPS) | -$0.91 |
Balance Sheet
The company has $13.02 million in cash and $5.72 million in debt, giving a net cash position of $7.30 million or $0.17 per share.
Cash & Cash Equivalents | 13.02M |
Total Debt | 5.72M |
Net Cash | 7.30M |
Net Cash Per Share | $0.17 |
Equity / Book Value | 17.53M |
Book Value Per Share | 0.40 |
Working Capital | 11.91M |
Cash Flow
In the last 12 months, operating cash flow was -$23.82 million and capital expenditures -$242,000, giving a free cash flow of -$24.06 million.
Operating Cash Flow | -23.82M |
Capital Expenditures | -242,000 |
Free Cash Flow | -24.06M |
FCF Per Share | -$0.56 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
IN8bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -75.02% |
Shareholder Yield | -75.02% |
Earnings Yield | -68.31% |
FCF Yield | -52.94% |
Analyst Forecast
The average price target for IN8bio is $8.25, which is 700.97% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $8.25 |
Price Target Difference | 700.97% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |